arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Dyadic International, Inc.

DYAI Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$0.40
▲ +3.1% Today
as of Oct 22, 16:48 ET
Last 30 days -4.76% Sep 14 → Oct 22
$0.37 $0.40 $0.42 $0.45 $0.48 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$0.40
High
$0.41
Low
$0.40
Volume
$44,202
Avg Vol
$199,392
Mkt Cap
$17M
P/E (TTM)
—
Beta
—
52w High
$1.60
52w Low
$0.34
Div Yield
—
Shares Out
$36M

DYAI earnings at a glance

The options market is pricing a move of about ±967.6% after the report, a range of roughly -$3.47 to $4.27 from today's $0.40. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±1.6% on average; after the most recent report on May 13, 2026 it moved -1.4%. That means options currently expect more movement than DYAI has typically delivered. DYAI beat the consensus EPS estimate in 0 of its last 2 reported quarters. Implied volatility is currently 82%. The share price of $0.40 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.34
$1.60
5% of range
Avg surprise (last 2)
-25.0%
Avg reaction (last 2)
-1.6%
0% positive
Latest IV / EM
8191%
EM ±967.6% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.57$-0.31$-0.04$0.22$0.49 Actual $-0.07Actual $-0.01Actual $-0.07Actual $-0.06Est $-0.06Actual $-0.06Est $-0.04Actual $-0.05Actual $-0.06 JunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-2M$-1M$-34,254$1M$2M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.06 — — — — financials
Wed May 13, 2026Mar/2026 $-0.05 — — +28.6% -1.4% earnings
Wed Nov 12, 2025Sep/2025 $-0.06 $-0.04 -50.0% — — earnings
Wed Aug 13, 2025Jun/2025 $-0.06 $-0.06 0.0% — — earnings
Wed May 14, 2025Mar/2025 $-0.07 — — — -1.9% earnings
Mon Sep 30, 2024Sep 2024 $-0.01 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.07 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$961,138$1M—$1M$966,630$393,572—$2M
Cost of revenue$984,165$791,840—$1M$613,591$297,658—$395,894
Gross profit————————
Operating income$-2M$-2M—$-2M$-2M$-2M—$-202,614
Net income$-2M$-2M—$-2M$-2M$-2M—$-203,460
EPS (diluted)$-0.06$-0.05—$-0.06$-0.06$-0.07—$-0.01

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$1M$4M$5M$6M$2M$5M$7M$6M
Inventory————————
Total current assets$6M$8M$10M$12M$7M$8M$10M$11M
Total assets$7M$8M$10M$12M$8M$8M$10M$11M
Long-term debt————————
Total liabilities$9M$8M$9M$9M$9M$7M$7M$7M
Total equity$-2M$-407,732$1M$3M$-529,701$923,611$2M$3M

Implied volatility — last 90 days

904%6894%12885%18875%24865% Jun 07 — IV 4521% · EM ±626.2%Jun 08 — IV 3846% · EM ±507.9%Jun 09 — IV 4313% · EM ±540.4%Jun 10 — IV 6964% · EM ±822.6%Jun 12 — IV 5375% · EM ±549.9%Jun 15 — IV 6687% · EM ±483.7%Jun 16 — IV 9778% · EM ±577.5%Jun 17 — IV 12133% · EM ±506.7%Jun 19 — IV 2141% · EM ±473.1%Jun 22 — IV 1556% · EM ±324.9%Jun 23 — IV 1941% · EM ±397.0%Jun 24 — IV 1673% · EM ±335.2%Jun 25 — IV 2549% · EM ±499.3%Jun 29 — IV 2886% · EM ±511.4%Jun 30 — IV 2649% · EM ±456.1%Jul 01 — IV 1907% · EM ±318.6%Jul 02 — IV 1611% · EM ±260.5%Jul 03 — IV 1667% · EM ±260.5%Jul 06 — IV 3134% · EM ±434.1%Jul 07 — IV 2179% · EM ±287.7%Jul 08 — IV 3363% · EM ±421.3%Jul 10 — IV 2519% · EM ±278.3%Jul 13 — IV 3463% · EM ±289.2%Jul 14 — IV 1853% · EM ±134.0%Jul 15 — IV 3886% · EM ±229.5%Jul 16 — IV 5332% · EM ±222.7%Jul 20 — IV 905% · EM ±213.7%Jul 21 — IV 1082% · EM ±251.7%Jul 22 — IV 1244% · EM ±284.6%Jul 23 — IV 1196% · EM ±268.9%Jul 24 — IV 1369% · EM ±302.5%Jul 30 — IV 1360% · EM ±266.4%Jul 31 — IV 1401% · EM ±268.2%Aug 03 — IV 2502% · EM ±443.4%Aug 04 — IV 2689% · EM ±463.0%Aug 05 — IV 1852% · EM ±309.4%Aug 06 — IV 2408% · EM ±389.4%Aug 07 — IV 1952% · EM ±305.0%Aug 10 — IV 2213% · EM ±306.5%Aug 11 — IV 1226% · EM ±161.9%Aug 12 — IV 3809% · EM ±477.3%Aug 13 — IV 3683% · EM ±435.1%Aug 14 — IV 5138% · EM ±567.7%Aug 17 — IV 5907% · EM ±493.4%Aug 18 — IV 6875% · EM ±497.3%Aug 20 — IV 15051% · EM ±628.6%Aug 24 — IV 3243% · EM ±677.2%Aug 25 — IV 3183% · EM ±651.2%Aug 26 — IV 3479% · EM ±696.9%Aug 28 — IV 3361% · EM ±643.2%Aug 31 — IV 4677% · EM ±828.7%Sep 01 — IV 4366% · EM ±751.7%Sep 02 — IV 5367% · EM ±896.6%Sep 03 — IV 5968% · EM ±965.3%Sep 04 — IV 4921% · EM ±768.9%Sep 07 — IV 5551% · EM ±768.9%Sep 08 — IV 6007% · EM ±793.4%Sep 09 — IV 5817% · EM ±728.8%Sep 11 — IV 7386% · EM ±816.1%Sep 14 — IV 12471% · EM ±1041.7%Sep 15 — IV 13595% · EM ±983.4%Sep 16 — IV 14509% · EM ±856.9%Sep 17 — IV 24866% · EM ±1038.5%Sep 21 — IV 5374% · EM ±1122.2%Sep 22 — IV 6721% · EM ±1375.0%Sep 24 — IV 7038% · EM ±1378.7%Sep 25 — IV 5589% · EM ±1069.7%Sep 28 — IV 5980% · EM ±1059.5%Sep 29 — IV 6106% · EM ±1051.5%Sep 30 — IV 6599% · EM ±1102.4%Oct 01 — IV 6908% · EM ±1117.3%Oct 02 — IV 5756% · EM ±899.5%Oct 06 — IV 6682% · EM ±882.4%Oct 08 — IV 8191% · EM ±967.6%

Sector peers

BCDA
BioCardia, Inc.
$15M $0.93-10.7%
JSPR
Jasper Therapeutics, Inc.
$20M $0.50-0.9%
TCRX
TScan Therapeutics, Inc.
$20M $0.22-3.6%
INAB
IN8bio, Inc.
$14M $0.99-13.5%
ESLA
Estrella Immunopharma, Inc.
$21M $0.73+81.8%
PASG
Passage Bio, Inc.
$14M $3.51-2.5%

DYAI earnings FAQ

What is DYAI's expected move for earnings?

Options currently price a move of about ±967.6%, or $3.87 per share either way from $0.40.

How does DYAI stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.6%, up 0 times and down 2 times.

What is DYAI's implied volatility?

DYAI's at-the-money implied volatility is about 82% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in